The Prognostic Significance of Terminal Deoxynucleotidyl Transferase (TDT) in Patients with Leukemias and Malignant Lymphomas

  • Roland Mertelsmann
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 145)


Since the first report of elevated terminal deoxynucleotidyl transferase (TdT) activity in leukemic cells from a patient with acute lymphoblastic leukemia (ALL)1, TdT has become one of the most widely studied phenotypic markers in hematopoietic neoplasias2–8.


Acute Lymphoblastic Leukemia Malignant Lymphoma Chronic Myelogenous Leukemia Terminal Deoxynuc1eotidy1 Transferase Blast Crisis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. McCaffrey, C. F. Smoler, and D. Baltimore, Terminal deoxynucleotidyl transferase in a case of childhood acute lymphoblastic leukemia, Proc. Nat. Acad. Sci. USA. 70:521 (1973).PubMedCrossRefGoogle Scholar
  2. 2.
    F.J. Bollum, Terminal deoxynucleotidyl transferase as a hematopoietic cell marker. Blood 54:1203 (1979).PubMedGoogle Scholar
  3. 3.
    S. M. Marks, D. Baltimore, and R. P. McCaffrey, Terminal transferase as predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia, N. Engl. J. Med. 298:812 (1978).PubMedCrossRefGoogle Scholar
  4. 4.
    G. Janossy, A. V. Hoffbrand, M. F. Greaves, K. Ganeshaguru, C. Pain, K. F. Bradstock, H. G. Prentice, H. E. M. Kzy and T. A. Lister, Terminal transferase enzyme assay and immunological membrane markers in the diagnosis of leukemia: a multiparameter analysis of 300 cases, Brit. J. Hemat. 44:221 (1980).CrossRefGoogle Scholar
  5. 5.
    K. F. Bradstock, A. V. Hoffbrand, K. Ganeshaguru, P. Llewellin, K. Patterson, B. Wonke, A. G. Prentice, M. Bennett, G. Pizzolo, F. J. Bollum, and G. Janossy, Terminal deoxynucleotidyl transferase expression in acute non-lymphoid leukemia: an analysis by immunofluorescence, Brit. J. Hemat. 47:133 (1981).CrossRefGoogle Scholar
  6. 6.
    G. Janossy, R. K. Woodruff, M. J. Pippart, G. Prentice, A. V. Hoffbrand, A. Paxton, T. A. Lister, C. Bunch, and M. F. Greaves, Relation of “lymphoid” phenotype and response to chemotherapy incorporating vincristine - prednisone in the acute phase of Ph’ positive leukemia. Cancer 43:426 (1979).PubMedCrossRefGoogle Scholar
  7. 7.
    R. Mertelsmann, I. Mertelsmann, B. Koziner, M. A. S. Moore, and B. D. Clarkson, Improved biochemical assay for terminal deoxynucleotidyl transferase in human blood cells: Results in 89 adult patients with lymphoid leukemias and malignant lymphomas in leukemic phase. Leuk. Res. 2:57 (1978).CrossRefGoogle Scholar
  8. 8.
    M. J. Modakr R. Mertelsmann, B. Koziner, R. Pahwa, M. A. S. Moore, B. D. Clarkson, and i?. A. Good, A micromethod for determination of terminal deoxynucleotidyl transferase (TdT) in the diagnostic evaluation of acute leukemias, J. Can. Res. Clin. Oncol. 98:91 (1980).CrossRefGoogle Scholar
  9. 9.
    R. Mertelsmann, D. A. Filippa, B. Koziner, E. Grossbard, J. Beck, S. Gupta, R. A. Good, M. A. S. Moore, P. H. Lieberman, and B. D. Clarkson, Correlation of biochemical and immunological markers with conventional morphology and clinical featues in 120 patients with malignant lymphomas. Adv. Exp. Med. Biol. 114:553 (1979).PubMedCrossRefGoogle Scholar
  10. 10.
    R. Mertelsmann, B. Koziner, D. A. Filippa, E. Grossbard, G. Incefy, M. A. S. Moore, and B. D. Clarkson, Clinical significance of TdT, surface markers and CFU-c in 297 patients with hematopoietic neoplasias, in: “Modern Trends in Human Leukemia III”, R. Neth, R. C. Gallo, P. H. Hof Schneider, and K. Mannweiler eds., Springer-Verlag, Berlin-Heidelberg-New York, (1979).Google Scholar
  11. 11.
    R. Mertelsmann, Leukaemien und maligne Lymphome. Phaenotypische und pathophysiologische Untersuchungen und ihre klinische Bedeutung, Georg Thieme Verlag, Stuttgart (1981).Google Scholar
  12. 12.
    R. Mertelsmann, B. Koziner, P. Ralph, D. Filippa, S. McKenzie, Z. A. Arlin, T. S. Gee, M. A. S. Moore, and B. D. Clarkson, Evidence for distinct lymphocytic and monocytic populations in a patient with terminal transferase positive acute leukemia. Blood 51:1051 (1978).PubMedGoogle Scholar
  13. 13.
    R. Mertelsmann, M. A. S. Moore, and B. D. Clarkson, Sequential marrow culture studies and terminal deoxynucleotidyl transferase activities in myelodysplastic syndromes, in: “Preleukemia”, F. Schmalzl, and K. P. Hellreigel eds., Springer Verlag, Berlin—Heidelberg-New York, (1979).Google Scholar
  14. 14.
    Z. A. Arlin, K. K. Jain, T. S. Gee, S. J. Kempin, R. S. K. Chaganti, and B. D. Clarkson, Improved response in terminal deoxynucleotidyl transferase (TdT) positive blastic phase of chronic myelogenous leukemia (CML) treated with an intensive regimen for acute lymphoblastic leukemia (ALL), ASCO Abstract #690, 509 (1981).Google Scholar
  15. 15.
    B. Koziner, D. A. Filippa, R. Mertelsmann, S. Gupta, B. Clarkson, R. A. Good, and F. P. Siegal, Characterization of malignant lymphomas in leukemic phase by multiple differentiation markers of mononuclear cells. Am. J. Med. 62:556 (1977).CrossRefGoogle Scholar
  16. 16.
    J. M. Bennett, D. Catovsky, Af. T. Daniel, G. Flandrin, D. A. G, Galton, H. Ré Gralnick and C. Sultan, Proposals for the Classification of the acute leukaemias, Brit. J. Hemat. 33:451 (1976).CrossRefGoogle Scholar
  17. 17.
    R. Mertelsmann, H. T. Thaler, L. To, T. S. Gee, S. McKenzie, P. Schauer, A. Friedman, Z. Arlin, C. Cirrincione, and B. Clarkson, Morphological classification, response to therapy and survival in 263 adult patients with acute non-lymphoblastic leukemia. Blood 56;773 (1980).PubMedGoogle Scholar
  18. 18.
    D. A. Filippa, P. H. Lieberman, R. A. Erlandson, B. Koziner, F. P. Siegal, A. Turnbull, A. Zimring, and R. A. Good, A study of malignant lymphomas using light and ultramicroscopic, cytochemical, and immunological techniques. Correlation with clinical features. Am J. Med. 64:259 (1978).PubMedCrossRefGoogle Scholar
  19. 19.
    H. Riehm, H. Gadner, G. Henze, H. J. Langermann, and E. Odenwald, The Berlin childhood acute lymphoblastic leukemia therapy study. Am. J. Pediatr. Hematol. Oncol. 2:299 (1980).Google Scholar
  20. 20.
    B. Clarkson, P. Schauer, R. Mertelsmann, T. S. Gee, Z. Arlin, S. Kempin, M. Bowling, P. Du four, C. Cirrincione and J. Burchenal, Results of intensive treatment of acute lymphoblastic leukemia in adults, in: “Cancer: Achievements, challenges and prospects for the 1980s”, J. H. Burchenal, and H. F. Oettgen, eds., Grune & Stratton, New York, 2:317 (1981).Google Scholar
  21. 21.
    E. Gold, R. Mertelsmann, D. Filippa, B. Koziner, T. H. Szatrowski, P. H. Lieberman, T. S. Gee, and B. Clarkson, Prognostic significance of surface markers, TdT, clinical parameters and three histopathological classifications in diffuse lymphomas. Am. Soc. Hematol. (Abstract) (1981).Google Scholar
  22. 22.
    B. Koziner, R. Mertelsmann, and D. A. Filippa, Adult lymphoid neoplasias of T and null cell types, in: “Differentiation of normal and neoplastic hematopoietic cells”, B. Clarksop P. A. Marks, J. E. Till, eds., Cold Spring Harbor Conferences on Cell Proliferation, 5:843 (1978).Google Scholar
  23. 23.
    R. I. Fisher, S. M. Hubbard, V. T. DeVlta, C. W. Berard, R. Wesley, J. Cossman and R.C. Yound, Factors predicting long- term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 58:45 (1981).PubMedGoogle Scholar
  24. 24.
    M. G. Kris, R. Mertelsmann, S. Jhanwar, R, Chaganti, T. H. Szatrowski, T. 5. Gee, S. Kempin, Z. Arlin, and B. Clarkson, Prognostic significance of pretreatment marrow cytogenetic studies in acute non-lymphocytic leukemia (ANLL), Am, Soc. Hemat. (Abstract), (1981).Google Scholar
  25. 25.
    E. J. Freireich, M. J. Keating E. A. Gehan, K. B. McCredie, G. P. Bodey, and T. Smith, Therapy of acute myelogenous leukemia. Cancer 42:874 (1978).PubMedCrossRefGoogle Scholar
  26. 26.
    P. Schauer, Z. Arlin, R. Mertelsmann, C. Cirrincione, A. Friedman, T. S. Gee, M. Bowling, S. Kempin, D. J. Straus, B. Koziner, S. Mackenzie, H. T. Thaler, P. Dufour, C. Little, C. Dellaquilla, S. Ellis and B. Clarkson, Treatment of acute lymphoblastic leukemia in adults. Results of the L-10 and L-IOM protocols, submitted for publication.Google Scholar
  27. 27.
    C. N. Coleman, J. R. Cohen, J. S. Burke and S. A. Rosenberg, Lymphoblastic lymphoma in adults: Results of a pilot protocol. Blood 57:679 (1981).PubMedGoogle Scholar
  28. 28.
    A. Bernard, L. Boumsell, E. L. Reinkerz, L. M. Nadler, J. Ritz, H. Coppin, Y. Richard, F. Valensi, J. Dausset, G. Flandrin, J. Lemerle, and S. F. Schlossman, Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: Evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood 57:1105 (1981).PubMedGoogle Scholar
  29. 29.
    M. A. S. Moore, Prediction of relapse and remission in AML by marrow culture criteria. Blood Cells 2:109 (1976).Google Scholar
  30. 30.
    H. E. Broxmeyer, E. Grossbard, N. Jacobsen and M. A. S. Moore, Persistence of inhibitory activity against normal bone-marrow cells during remission of acute leukemia, N. Engl. J. Med. 301:346 (1979).PubMedCrossRefGoogle Scholar
  31. 31.
    R. Mertelsmann, S. Gillis, B. Koziner, and M. A. S. Moore, Abnormal T cell growth factor (Interleukin 2) response pattern in human leukemias exhibiting high terminal transferase activity, in: Differentiation factors in cancer M. A. S. Moore, eds., Raven Press, New York, (1981) in press.Google Scholar
  32. 32.
    R. Mertelsmann, S. Gillis, G. Steinmann, P. Ralph, M. Stiehm, B. Koziner, and M. A. S. Moore, T-cell growth factor (Interleukin-2) and terminal transferase in human leukemias and lymphoblastic cell lines, Blut, (1981) in press.Google Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Roland Mertelsmann
    • 1
  1. 1.Developmental Hematopoiesis Laboratory and Hematology/Lymphoma Service, Department of MedicineMemorial Sloan-Kettering Cancer Center, N.Y.N.Y.USA

Personalised recommendations